Back
Full-text
Journal article

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

  • Banales JM Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain. jesus.banales@biodonostia.org.
  • Marin JJG National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), San Sebastian, Spain.
  • Lamarca A Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Rodrigues PM Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
  • Khan SA Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Roberts LR Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
  • Cardinale V Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.
  • Carpino G Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Rome, Italy.
  • Andersen JB Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Braconi C Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Calvisi DF Institute of Pathology, University of Regensburg, Regensburg, Germany.
  • Perugorria MJ Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
  • Fabris L Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
  • Boulter L MRC-Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Macias RIR National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), San Sebastian, Spain.
  • Gaudio E Division of Human Anatomy, Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
  • Alvaro D Department of Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.
  • Gradilone SA The Hormel Institute, University of Minnesota, Austin, MN, USA.
  • Strazzabosco M Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
  • Marzioni M Clinic of Gastroenterology and Hepatology, Universita Politecnica delle Marche, Ancona, Italy.
  • Coulouarn C INSERM, Université de Rennes, Rennes, France.
  • Fouassier L Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
  • Raggi C Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Invernizzi P Division of Gastroenterology and Center of Autoimmune Liver Diseases, Department of Medicine and Surgery, San Gerardo Hospital, University of Milano, Bicocca, Italy.
  • Mertens JC Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zürich, Switzerland.
  • Moncsek A Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zürich, Switzerland.
  • Rizvi S Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
  • Heimbach J Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Koerkamp BG Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands.
  • Bruix J National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), San Sebastian, Spain.
  • Forner A National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), San Sebastian, Spain.
  • Bridgewater J Department of Medical Oncology, UCL Cancer Institute, London, UK.
  • Valle JW Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Gores GJ Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Show more…
  • 2020-07-02
Published in:
  • Nature reviews. Gastroenterology & hepatology. - 2020
Bile Duct Neoplasms
Cholangiocarcinoma
Humans
English Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/168795
Statistics
Document views: 120 File downloads:
  • Full-text: 0